Furet P - Search Results

1

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Vaupel A, Holzer P, Ferretti S, Guagnano V, Kallen J, Mah R, Masuya K, Ruetz S, Rynn C, Schlapbach A, Stachyra T, Stutz S, Todorov M, Jeay S, Furet P. Vaupel A, et al. Among authors: furet p. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3404-3408. doi: 10.1016/j.bmcl.2018.08.027. Epub 2018 Aug 26. Bioorg Med Chem Lett. 2018. PMID: 30217415

2

Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.

Bühlmayer P, Criscione L, Fuhrer W, Furet P, de Gasparo M, Stutz S, Whitebread S. Bühlmayer P, et al. Among authors: furet p. J Med Chem. 1991 Oct;34(10):3105-14. doi: 10.1021/jm00114a021. J Med Chem. 1991. PMID: 1920360

3

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.

Trinks U, Buchdunger E, Furet P, Kump W, Mett H, Meyer T, Müller M, Regenass U, Rihs G, Lydon N, et al. Trinks U, et al. Among authors: furet p. J Med Chem. 1994 Apr 1;37(7):1015-27. doi: 10.1021/jm00033a019. J Med Chem. 1994. PMID: 8151612

4

4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase.

Stanek J, Caravatti G, Frei J, Furet P, Mett H, Schneider P, Regenass U. Stanek J, et al. Among authors: furet p. J Med Chem. 1993 Jul 23;36(15):2168-71. doi: 10.1021/jm00067a014. J Med Chem. 1993. PMID: 8340919

5

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P. Traxler P, et al. Among authors: furet p. J Med Chem. 1997 Oct 24;40(22):3601-16. doi: 10.1021/jm970124v. J Med Chem. 1997. PMID: 9357527

6

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

Imbach P, Capraro HG, Furet P, Mett H, Meyer T, Zimmermann J. Imbach P, et al. Among authors: furet p. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6. doi: 10.1016/s0960-894x(98)00691-x. Bioorg Med Chem Lett. 1999. PMID: 9990463

7

Highly potent inhibitors of the Grb2-SH2 domain.

Schoepfer J, Fretz H, Gay B, Furet P, García-Echeverría C, End N, Caravatti G. Schoepfer J, et al. Among authors: furet p. Bioorg Med Chem Lett. 1999 Jan 18;9(2):221-6. doi: 10.1016/s0960-894x(98)00701-x. Bioorg Med Chem Lett. 1999. PMID: 10021933

8

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.

Traxler P, Green J, Mett H, Séquin U, Furet P. Traxler P, et al. Among authors: furet p. J Med Chem. 1999 Mar 25;42(6):1018-26. doi: 10.1021/jm980551o. J Med Chem. 1999. PMID: 10090785

9

Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility.

Gay B, Suarez S, Weber C, Rahuel J, Fabbro D, Furet P, Caravatti G, Schoepfer J. Gay B, et al. Among authors: furet p. J Biol Chem. 1999 Aug 13;274(33):23311-5. doi: 10.1074/jbc.274.33.23311. J Biol Chem. 1999. PMID: 10438507 Free article.

10

Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2.

Caravatti G, Rahuel J, Gay B, Furet P. Caravatti G, et al. Among authors: furet p. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1973-8. doi: 10.1016/s0960-894x(99)00299-1. Bioorg Med Chem Lett. 1999. PMID: 10450965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page